102460.KS
REYON Pharmaceutical Co., Ltd.
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 9,360.00
−3.31%Year over year
Reported trailing growth
- Revenue
- -4.5%
- EBITDA
- —
- EBIT
- -84.8%
- EPS
- —
- Free cash flow
- +108.2%
- Operating cash flow
- +427.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -1.8%
- EBITDA
- -74.4%
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- +61.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026